



Astellas, Independent Medical Education and Pfizer Global Medical Grants & Partnerships

Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)

Release Date: November 11, 2024

I. Background

Astellas and Pfizer Inc. (collectively, the Companies) are committed to supporting high quality, evidence-based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and treatment. The intent of this Call for Grant Applications (CGA) is to seek applications for independent Continuing Medical Education / Continuing Education (CME/CE) designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence and performance of healthcare professionals, and advance patient health outcomes. “Independent” means that the projects funded are the full responsibility of the recipient organization. The Companies shall have no influence over any aspect of the supported projects and only ask for status updates, quarterly interim and final outcomes reports including a description of the overall impact of the project.

When responding to this CGA, please adhere to the following principles and established guidelines for Astellas’ IME grant application process. All applications must be submitted online through the Astellas Grant Management System, accessible at www.astellasgrants.com.

II. Eligibility

Geographic Scope:	Global - priority target audience is outside of the United States. At a minimum, proposals must have multi-country/regional reach.
Applicant Eligibility Criteria:	Eligible applicants include Global Medical Education Providers with experience in executing IME with the capability of multiple language translations and global distribution channels. Collaborations between organizations and within institutions are acceptable. Please note all partners must have a relevant role and the requesting Organization must lead the project. For all US-based organizations only, the accrediting organization must be the primary requestor on the grant application.

III. Requirements

Date CGA Issued:	November 11, 2024
Application Deadline:	December 24, 2024
Anticipated Grant Decision Date:	January 31, 2025
Clinical Area-Education:	Oncology – Urothelial Carcinoma
Target Program Start Date:	March 2025
Specific Education Gaps To Be Addressed:	<p>The purpose of this CGA is to encourage Organizations with ex - US experience to submit grant applications for independent either accredited or non-accredited activities designed to enhance understanding of the management of urothelial carcinoma (UC). Knowledge gaps in Urothelial Carcinoma which have been identified in the public healthcare landscape include:</p> <ul style="list-style-type: none"> • Evolving therapeutic options for patients with locally advanced (la) or metastatic urothelial carcinoma (mUC) <ul style="list-style-type: none"> ○ Emerging treatment options in the 1L setting and the holistic management of patients with UC, including combination regimens and optimal sequencing ○ Recent updates to treatment guidelines • Adverse event management in current and emerging treatment options in la/mUC <ul style="list-style-type: none"> ○ Early identification and management of adverse events associated with UC treatment within the multidisciplinary team ○ Importance of patient education • The future treatment landscape in Muscle Invasive Bladder Cancer (MIBC) setting <ul style="list-style-type: none"> ○ Perioperative approach in MIBC setting ○ The role of multi-disciplinary team in MIBC management ○ Impact of systemic therapy in MIBC on la/mUC treatment choice <p>Proposals must address at least two of the three knowledge gaps identified above. Proposals that address multiple gaps from the above list, and activities with a global reach and innovative dissemination and engagement approaches, will be prioritized. The primary language of the program must be in English. Language translation must be included in any proposed enduring components in one of the following: Portuguese, Japanese, German, Spanish and/or French.</p>

<p>How to Submit:</p>	<p>Please go to www.astellasgrants.com. LOGIN -Grants for Education and sign in. First-time users will need to “REGISTER NOW” and create a profile.</p> <p>Select the following: Therapeutic Area: Oncology Disease State: Urothelial Cancer</p> <p>Requirements for submission: You must include “2024-CGA-Global UC-01” in the “Activity Title” of your program’s online submission prior to the title.</p> <p>Complete all required sections of the online application and upload the requested documents.</p> <p>If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page.</p> <p>IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed.</p>
<p>Recommended Target Audiences/ Formats:</p>	<ul style="list-style-type: none"> • Medical oncologists responsible for treatment decisions and inclusion of multidisciplinary team members caring for patients with UC. • Urologists in countries where they are the primary point of care of patients and inclusion of multidisciplinary team members caring for patients with UC. • Other care team members, including but not limited to, pharmacists and nurses involved in AE management. <p>Proposals for independent medical education may include: All activity formats including live, virtual, on-demand (enduring), print materials, utilizing innovative communication channels, apps, social media, digital programs, podcasts and resources or tools for clinical practice use.</p>
<p>Expected Approximate Monetary Range of Grant Applications:</p>	<p>Each Individual event/activity request will be reviewed. The total budget for this CGA is \$700,000 which is intended to support multiple activities and/or grants. Applicants must complete all budget fields in the system. Budget breakdown must include separate costs for language translations.</p> <p>Funding of larger grant amounts will be considered for requests that include multiple activities, such as several live/webinar events, enduring activities, and supportive materials and tools. The amount of any grant funded by the Companies for any project may vary from the amount requested. <i>Preference will be given to initiatives with multiple funding sources in addition to Astellas/Pfizer.</i></p>

IV. Terms and Conditions

1. This CGA process does not commit the Companies to award a specific grant or provide a grant of a specific amount if one is awarded.
2. This CGA process does not commit the Companies to pay for any costs incurred in the preparation of a response to this CGA process.
3. The Companies reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety at any time for any reason.
4. All communications about the CGA must be sent to the Astellas Independent Medical Education (IME) team at <http://www.astellasgrants.com/>. Applicants should not contact other departments within Astellas regarding this CGA. Failure to comply may affect the acceptance of your application.
5. The decision by the Companies to provide a grant will not be determined in a manner that considers the volume or value of any business otherwise generated between Astellas or Pfizer Inc. and any applicant.
6. Applicant shall have complete control over the content, development and implementation of the education programs and/or materials, including, if applicable, the selection of faculty. Any information provided as part of the program regarding any products, including, without limitation, Astellas and/or Pfizer Inc. products, shall be objective and based on scientific methods generally accepted in the medical community.
7. Upon approval by the Companies of a Proposal, the successful Organization will receive a formal Letter of Agreement (LOA) confirming the grant for signature. This LOA will cite specific responsibilities of the Organization and also indicate how to appropriately acknowledge both Astellas and Pfizer Inc. for the provision of financial grant support for the proposed activity. Financial funding will not be provided until a signed LOA is returned to the Companies by the Organization.